Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Flonoltinib vs Ruxolitinib in Intermediate- or High-risk Myelofibrosis
ChiCTR2600118347Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of flonoltinib in myelofibrosis (MF) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of subjects with ≥35% reduction in spleen volume from baseline at Week 24. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
flonoltinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on ChiCTR2600118347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118347.